Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.68 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.68 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.68 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27173308 | 0.86 | GRIN1 (0.64) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL29209237 | 0.85 | GRIN1 (0.67) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19688701 | 0.85 | GRIN1 (0.67) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3997047 | 0.84 | SLC6A4 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3993491 | 0.83 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3990887 | 0.81 | GRIN1 (0.55) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Ketamine SCHEMBL28630569 | 0.81 | GRIN1 (0.94) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19400501 | 0.81 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL4407465 | 0.81 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19688879 | 0.81 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802480-B1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF (2R,6R)-HYDROXYNORKETAMINE | US HEALTH (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192594-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-06-22 | — | — | US | disclosed |
| US-11613514-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-03-28 | — | — | US | disclosed |
| US-11186539-B2 | Process for synthesis and purification of (2R,6R)-hydroxynorketamine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210246099-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF (2R,6R)-HYDROXYNORKETAMINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-12 | — | — | US | disclosed |
| US-20210139411-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-13 | — | — | US | disclosed |
| EP-3802480-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF (2R,6R)-HYDROXYNORKETAMINE | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10919842-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190135732-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-20190083420-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-21 | — | — | US | disclosed |
| EP-3433230-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3432869-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | THE UNITED STATES OF AMERICA, represented by the S (US) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017165878-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165877-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246099-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF (2R,6R)-HYDROXYNORKETAMINE | KHK, HK1, HK2 | GRIN1 1659/4885GRIN2A 895/4885SLC6A4 763/4885 |
| US-20190083420-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | HTR2A, HTR6, HTR2C | GRIN1 196/4885GRIN2A 37/4885SLC6A4 20/4885 |
| US-10919842-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | PDXK, GCK, KHK | GRIN1 528/4885GRIN2A 404/4885SLC6A4 1469/4885 |
| US-20190135732-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | PDXK, GCK, KHK | GRIN1 528/4885GRIN2A 404/4885SLC6A4 1469/4885 |
| US-20230192594-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | GRM6, HYPK, SYMPK | GRIN1 137/4885GRIN2A 98/4885SLC6A4 1093/4885 |
| US-11613514-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | PDXK, GCK, KHK | GRIN1 528/4885GRIN2A 404/4885SLC6A4 1469/4885 |
| US-11186539-B2 | Process for synthesis and purification of (2R,6R)-hydroxynorketamine | KHK, HK1, HK2 | GRIN1 1659/4885GRIN2A 895/4885SLC6A4 763/4885 |
| US-20210139411-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | PDXK, GCK, KHK | GRIN1 528/4885GRIN2A 404/4885SLC6A4 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.